European Alliance to accelerate new concepts in HIV Vaccine research

Wednesday, 27 January, 2016
Despite enormous progress in the prevention and treatment of HIV/AIDS, the global response cannot keep pace: 35 million people are living with HIV worldwide with around 6,000 new infections each day. Numerous HIV prevention strategies, though proven successful, are difficult to sustain long-term. A vaccine still represents the most effective tool in the combat against HIV from a public health perspective.

To date, many prophylactic and therapeutic vaccine concepts have been developed and several efficacy trials have been conducted but with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at the early stage of vaccine development to mitigate the risks of failure.To address these complex and challenging scientific issues, EHVA aims to develop a Multidisciplinary Vaccine Platform through a global and innovative alliance.

More at INSERM website

European HIV Vaccine Alliance (EHVA): an EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates
Project Acronym: